Up-front blinatumomab improves MRD clearance and outcome in adult Ph– B-lineage ALL: the GIMEMA LAL2317 phase 2 studyRenato Bassan, Robin Foà, Loredana Elia et al.|Blood|2025Cited by 37
Sequential Chemotherapy and Blinatumomab to Improve Minimal Residual Disease in Adult Ph- B-Lineage Acute Lymphoblastic Leukemia. Final Results of the Phase II Gimema LAL2317 TrialSabina Chiaretti, Renato Bassan, Irene Della Starza et al.|Blood|2023Cited by 28
Measurable Residual Disease Monitoring for Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ALL) in the Setting of the Gimema ALL2820 TrialMarco Beldinanzi, Sabina Chiaretti, Vittorio Bellomarino et al.|Blood|2024Cited by 0